This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Bariatric Arterial Embolization for Morbid Obesity...
Clinical trial

Bariatric Arterial Embolization for Morbid Obesity (BAEMO)

Read time: 1 mins
Last updated:1st May 2016

The purpose of this study is to evaluate the safety and effectiveness of left gastric artery embolization(bariatric arterial embolization) for morbid obesity. When the target vessel is blocked, some of the body's signals for feeling hungry will be suppressed and lead to weight loss.

Although there are many ways to treat morbid obesity, surgery is currently the only effective method to be confirmed. But surgical treatment is likely to carry a high risk of treatment-related complications, such as fistula or intestinal obstruction, etc. This study is designed to help treat obesity using a method of transvascular interventional therapy, which is minimally invasive and non-surgical.


Study Type: Interventional
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Bariatric Arterial Embolization for Morbid Obesity
Estimated Enrollment: 50
Study Start Date: May 2016
Estimated Study Completion Date: May 2018
Estimated Primary Completion Date: October 2017 (Final data collection date for primary outcome measure)

Arms:
- Experimental:
left gastric artery embolization
- Active Comparator: healthy diet and exercise

Category Value
Study start date 2016-05-01

View full details